International Journal of Hematology

, 79:495

Impact of Cytogenetics on Outcome of Stem Cell Transplantation for Acute Myeloid Leukemia in First Remission: A Large-Scale Retrospective Analysis of Data from the Japan Society for Hematopoietic Cell Transplantation

  • Hiroyasu Ogawa
  • Kazuhiro Ikegame
  • Manabu Kawakami
  • Satoshi Takahashi
  • Hisashi Sakamaki
  • Takahiro Karasuno
  • Hiroshi Sao
  • Yoshihisa Kodera
  • Noriyuki Hirabayashi
  • Shinichiro Okamoto
  • Mine Harada
  • Koji Iwato
  • Atsuo Maruta
  • Mitsune Tanimoto
  • Keisei Kawa
Article

DOI: 10.1532/IJH97.03166

Cite this article as:
Ogawa, H., Ikegame, K., Kawakami, M. et al. Int J Hematol (2004) 79: 495. doi:10.1532/IJH97.03166

Abstract

On the basis of transplantation data from the Japan Society for Hematopoietic Cell Transplantation, we retrospectively analyzed the impact of cytogenetics at diagnosis on the outcome of transplantation in 628 patients with acute myeloid leukemia who underwent autologous (n = 200), allogeneic related (n = 363), or allogenic unrelated (n = 65) stem cell transplantation (SCT) at first complete remission. For autologous SCT, patients at good cytogenetic risk had a significantly lower relapse rate (P = .017) and a significantly higher event-free survival (EFS) (P = .013) compared with those at intermediate risk. For allogeneic SCT, patients at good cytogenetic risk had a significantly lower relapse rate (P = .019) and insignificantly higher EFS (P = .093) than those at poor risk. For unrelated SCT, there was no significant difference in relapse rate or EFS between patients at good risk and those at intermediate risk. Comparison of the 3 transplantation modalities revealed that autologous SCT patients had a significantly higher incidence of relapse compared with related or unrelated SCT patients in the intermediate-risk group but not in the good-risk group. However, there were no significant differences in EFS among the 3 transplant modalities in either of these 2 risk groups. In multivariate analysis, cytogenetics was found to be an independent predictor of relapse as well as of treatment failure.

Key words

Acute myeloid leukemiaCytogeneticsAutologous stem cell transplantationAllogeneic related stem cell transplantationAllogeneic unrelated stem cell transplantation

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Hiroyasu Ogawa
    • 1
  • Kazuhiro Ikegame
    • 1
  • Manabu Kawakami
    • 1
  • Satoshi Takahashi
    • 2
  • Hisashi Sakamaki
    • 3
  • Takahiro Karasuno
    • 4
  • Hiroshi Sao
    • 5
  • Yoshihisa Kodera
    • 6
  • Noriyuki Hirabayashi
    • 7
  • Shinichiro Okamoto
    • 8
  • Mine Harada
    • 9
  • Koji Iwato
    • 10
  • Atsuo Maruta
    • 11
  • Mitsune Tanimoto
    • 12
  • Keisei Kawa
    • 13
  1. 1.Department of Molecular MedicineOsaka University Graduate School of MedicineOsakaJapan
  2. 2.Division of Molecular TherapyAdvanced Clinical Research Center, Institute of Medical Science, University of TokyoTokyo
  3. 3.Bone Marrow Transplantation TeamTokyo Metropolitan Komagome HospitalTokyo
  4. 4.Fifth Department of Internal MedicineOsaka Medical Center for Cancer and Cardiovascular DiseasesOsaka
  5. 5.Department of HematologyMeitetsu HospitalNagoya
  6. 6.Department of Internal MedicineJapanese Red Cross Nagoya First HospitalNagoya
  7. 7.Department of HematologyNagoya Daini Red Cross HospitalNagoya
  8. 8.Department of MedicineKeio University School of MedicineTokyo
  9. 9.Department of Medicine and Biosystemic ScienceKyushu University Graduate School of Medical SciencesFukuoka
  10. 10.Department of Internal MedicineHiroshima Red Cross Hospital and Atomic-Bomb Survivors HospitalHiroshima
  11. 11.Department of HematologyKanagawa Cancer CenterKanagawa
  12. 12.Department of HematologyOncology, and Respiratory Disease, Okayama University Graduate Schools of Medicine and DentistryOkayama
  13. 13.Department of PediatricsOsaka Medical Center and Research Institute for Maternal and Child HealthOsakaJapan